STABILITY AND COMPATIBILITY OF FLUOROURACIL AND MANNITOL DURING SIMULATED Y-SITE ADMINISTRATION

被引:1
|
作者
WOLOSCHUK, DMM
WERMELING, JR
PRUEMER, JM
机构
[1] WILLIAM S MIDDLETON MEM VET ADM MED CTR,NEUROL RES LAB,MADISON,WI 53705
[2] UNIV CINCINNATI HOSP,CINCINNATI,OH
来源
AMERICAN JOURNAL OF HOSPITAL PHARMACY | 1991年 / 48卷 / 10期
关键词
ADDITIVES; ANTINEOPLASTIC AGENTS; CONCENTRATION; DEXTROSE; DIURETICS; FLUOROURACIL; INCOMPATIBILITIES; INJECTIONS; MANNITOL; SODIUM CHLORIDE; STABILITY; VEHICLES;
D O I
10.1093/ajhp/48.10.2158
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability and compatibility of fluorouracil admixtures with mannitol during simulated Y-site administration was studied. Fluorouracil injection 50 mg/mL was diluted with 5% dextrose injection, 0.9% sodium chloride injection, and 5% dextrose and 0.45% sodium chloride injection to final concentrations of 1 and 2 mg/mL. Combinations of fluorouracil admixtures with 20% mannitol injection were made using equal volumes in glass test tubes; immediately after mixing and at one, two, and four hours, the samples were examined for visual incompatibilities. Duplicate combinations of fluorouracil admixtures with 20% mannitol injection were made using equal volumes in plastic syringes; immediately after mixing with internal standard in glass test tubes and at 2, 4, 8, and 24 hours, samples were removed for chemical analysis. A high-performance liquid chromatographic assay was used to determine fluorouracil concentrations. No evidence of precipitation, color change, or haze was observed. During the 24-hour study, fluorouracil concentrations remained within 6% of initial concentrations for all combinations with mannitol. Fluorouracil 1 and 2 mg/mL in 5% dextrose injection, 0.9% sodium chloride injection, and 5% dextrose and 0.45% sodium chloride injection was chemically stable and visually compatible when combined with 20% mannitol injection during simulated Y-site administration.
引用
下载
收藏
页码:2158 / 2160
页数:3
相关论文
共 50 条
  • [21] Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration
    Hall, PD
    Yui, D
    Lyons, S
    Bosso, JA
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (02) : 185 - 189
  • [22] Compatibility of treprostinil sodium and dopamine hydrochloride during simulated Y-site administration
    Bustin, Anna
    Ramsey, E. Zachary
    Hanna, Brian D.
    Kaushal, Gagan
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (08) : 649 - 657
  • [23] In vitro compatibility of various cardioactive drugs during simulated Y-site administration
    Humbert-Delaloye, Valia
    Berger-Gryllaki, Markoulina
    Voirol, Pierre
    Gattlen, Laurent
    Pannatier, Andre
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2013, 20 (02): : 110 - 116
  • [24] Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration
    Chan, Pak
    Bishop, Amanda
    Kuplec, Thomas C.
    Trissel, Lawrence A.
    Gole, Dilip
    Jimidar, Ilias M.
    Vermeersch, Hans
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (16) : 1545 - 1551
  • [25] Compatibility of selected critical care drugs during simulated Y-site administration
    Yamashita, SK
    Walker, SE
    Choudhury, T
    Iazzetta, J
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (09) : 1048 - 1051
  • [26] Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration
    Trissel, LA
    Gilbert, DL
    Martinez, JF
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (01) : 56 - 60
  • [27] Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration
    Trissel, LA
    Martinez, JF
    Gilbert, DL
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (15) : 1735 - 1741
  • [28] Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration
    Trissel, LA
    Gilbert, DL
    Martinez, JF
    Kim, MC
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (19) : 2192 - 2196
  • [29] Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration
    Patel, K
    Hursting, MJ
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (13) : 1381 - 1384
  • [30] Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
    Foushee, Jaime A.
    Fox, Laura M.
    Gormley, Lyndsay R.
    Lineberger, Megan S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (06) : 483 - 486